These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9484790)
1. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9. Cummings J; Spanswick VJ; Gardiner J; Ritchie A; Smyth JF Biochem Pharmacol; 1998 Feb; 55(3):253-60. PubMed ID: 9484790 [TBL] [Abstract][Full Text] [Related]
2. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004 [TBL] [Abstract][Full Text] [Related]
3. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Plumb JA; Gerritsen M; Workman P Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885 [TBL] [Abstract][Full Text] [Related]
4. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022 [TBL] [Abstract][Full Text] [Related]
5. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Begleiter A; Leith MK; Curphey TJ Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837 [TBL] [Abstract][Full Text] [Related]
6. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Walton MI; Bibby MC; Double JA; Plumb JA; Workman P Eur J Cancer; 1992; 28A(10):1597-600. PubMed ID: 1389472 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Phillips RM Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172 [TBL] [Abstract][Full Text] [Related]
8. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948 [TBL] [Abstract][Full Text] [Related]
9. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984 [TBL] [Abstract][Full Text] [Related]
10. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Smitskamp-Wilms E; Hendriks HR; Peters GJ Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519 [TBL] [Abstract][Full Text] [Related]
11. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456 [TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Smitskamp-Wilms E; Peters GJ; Pinedo HM; van Ark-Otte J; Giaccone G Biochem Pharmacol; 1994 Apr; 47(8):1325-32. PubMed ID: 7514407 [TBL] [Abstract][Full Text] [Related]
13. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Walton MI; Smith PJ; Workman P Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284 [TBL] [Abstract][Full Text] [Related]
14. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Plumb JA; Workman P Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Loadman PM; Phillips RM; Lim LE; Bibby MC Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Workman P; Binger M; Kooistra KL Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843 [TBL] [Abstract][Full Text] [Related]
17. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. Phillips RM Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133 [TBL] [Abstract][Full Text] [Related]
18. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Smitskamp-Wilms E; Giaccone G; Pinedo HM; van der Laan BF; Peters GJ Br J Cancer; 1995 Oct; 72(4):917-21. PubMed ID: 7547240 [TBL] [Abstract][Full Text] [Related]
19. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829 [TBL] [Abstract][Full Text] [Related]
20. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]